ICI-based immunotherapy consists of neutralizing antibodies against negative regulators of immune function, such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), and PD-1 ligand 1 (PD-L1), thereby restricting the ability of residual tumor cells to escape the cytotoxic immune program [147]. The gene discussed is CTLA4; the disease is neoplasm.